文献速递流行病学与生物统计临床试验与 GCP

妊娠期糖尿病二甲双胍与胰岛素治疗后新生儿、婴儿及儿童期生长:系统综述与Meta分析

Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2019-08-06

该系统综述与Meta分析纳入28项随机对照研究(n=3,976),比较妊娠期糖尿病二甲双胍与胰岛素治疗对子代生长的影响。二甲双胍组新生儿出生体重和体重指数更低,巨大儿和大于胎龄儿风险更低;但婴儿期(18-24月龄)体重更高,儿童中期(5-9岁)BMI更高。

要点

  • 二甲双胍组新生儿出生体重较胰岛素组低107.7 g,巨大儿风险更低(OR 0.59)。
  • 二甲双胍暴露婴儿18-24月龄体重较胰岛素组高440 g(平均差)。
  • 二甲双胍暴露儿童5-9岁BMI较胰岛素组高0.78 kg/m2(平均差)。

核心结论

  • 宫内暴露于二甲双胍后新生儿较胰岛素暴露新生儿显著更小,但二甲双胍暴露儿童呈现加速的出生后生长,导致婴儿期更重、儿童中期BMI更高。
  • 低出生体重和出生后追赶生长模式与不良长期心血管代谢结局相关,提示需进一步研究宫内二甲双胍暴露后的纵向围产期和儿童期结局。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Ovid Embase、Medline、Web of Science、ClinicalTrials.gov和Cochrane数据库(从建库至2019年2月26日)。
  • 纳入妊娠期糖尿病孕妇随机接受二甲双胍与胰岛素治疗的随机对照试验和前瞻性随机对照研究,共28项研究(n=3,976名参与者)。
  • 两名评价者独立评估文献合格性和偏倚风险,分歧由第三名评价者解决。

主要发现

  • 无研究报告胎儿生长参数;19项研究(n=3,723名新生儿)报告新生儿生长指标。
  • 二甲双胍组新生儿出生体重较胰岛素组低(平均差-107.7 g,95%CI -182.3至-32.7,I²=83%,p=0.005)。
  • 二甲双胍组新生儿体重指数较胰岛素组低(平均差-0.13 kg/m³,95%CI -0.26至0.00,I²=0%,p=0.04)。
  • 二甲双胍组巨大儿风险更低(OR 0.59,95%CI 0.46至0.77,p<0.001),大于胎龄儿风险更低(OR 0.78,95%CI 0.62至0.99,p=0.04)。
  • 两组新生儿身高和小于胎龄儿发生率无差异;2项研究(n=411名婴儿)报告18-24月龄生长指标,二甲双胍暴露婴儿较胰岛素暴露组显著更重(平均差440 g,95%CI 50至830,I²=4%,p=0.03)。

局限性

  • 二甲双胍剂量存在异质性。
  • 妊娠期糖尿病诊断标准存在异质性。
  • 儿童期结局报告稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin is increasingly offered as an acceptable and economic alternative to insulin for treatment of gestational diabetes mellitus (GDM) in many countries. However, the impact of maternal metformin treatment on the trajectory of fetal, infant, and childhood growth is unknown. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and the Cochrane database were systematically searched (from database inception to 26 February 2019). Outcomes of GDM-affected pregnancies randomised to treatment with metformin versus insulin were included (randomised controlled trials and prospective randomised controlled studies) from cohorts including European, American, Asian, Australian, and African women. Studies including pregnant women with pre-existing diabetes or non-diabetic women were excluded, as were trials comparing metformin treatment with oral glucose-lowering agents other than insulin. Two reviewers independently assessed articles for eligibility and risk of bias, and conflicts were resolved by a third reviewer. Outcome measures were parameters of fetal, infant, and childhood growth, including weight, height, BMI, and body composition. In total, 28 studies (n = 3,976 participants) met eligibility criteria and were included in the meta-analysis. No studies reported fetal growth parameters; 19 studies (n = 3,723 neonates) reported measures of neonatal growth. Neonates born to metformin-treated mothers had lower birth weights (mean difference -107.7 g, 95% CI -182.3 to -32.7, I2 = 83%, p = 0.005) and lower ponderal indices (mean difference -0.13 kg/m3, 95% CI -0.26 to 0.00, I2 = 0%, p = 0.04) than neonates of insulin-treated mothers. The odds of macrosomia (odds ratio [OR] 0.59, 95% CI 0.46 to 0.77, p < 0.001) and large for gestational age (OR 0.78, 95% CI 0.62 to 0.99, p = 0.04) were lower following maternal treatment with metformin compared to insulin. There was no difference in neonatal height or incidence of small for gestational age between groups. Two studies (n = 411 infants) reported measures of infant growth (18-24 months of age). In contrast to the neonatal phase, metformin-exposed infants were significantly heavier than those in the insulin-exposed group (mean difference 440 g, 95% CI 50 to 830, I2 = 4%, p = 0.03). Three studies (n = 520 children) reported mid-childhood growth parameters (5-9 years). In mid-childhood, BMI was significantly higher (mean difference 0.78 kg/m2, 95% CI 0.23 to 1.33, I2 = 7%, p = 0.005) following metformin exposure than following insulin exposure, although the difference in absolute weights between the groups was not significantly different (p = 0.09). Limited evidence (1 study with data treated as 2 cohorts) suggested that adiposity indices (abdominal [p = 0.02] and visceral [p = 0.03] fat volumes) may be higher in children born to metformin-treated compared to insulin-treated mothers. Study limitations include heterogeneity in metformin dosing, heterogeneity in diagnostic criteria for GDM, and the scarcity of reporting of childhood outcomes. CONCLUSIONS: Following intrauterine exposure to metformin for treatment of maternal GDM, neonates are significantly smaller than neonates whose mothers were treated with insulin during pregnancy. Despite lower average birth weight, metformin-exposed children appear to experience accelerated postnatal growth, resulting in heavier infants and higher BMI by mid-childhood compared to children whose mothers were treated with insulin. Such patterns of low birth weight and postnatal catch-up growth have been reported to be associated with adverse long-term cardio-metabolic outcomes. This suggests a need for further studies examining longitudinal perinatal and childhood outcomes following intrauterine metformin exposure. This review protocol was registered with PROSPERO under registration number CRD42018117503.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Tarry-Adkins JL, Aiken CE, Ozanne SE, et al. Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis. PLoS Med. 2019. PMID: 31386659. doi:10.1371/journal.pmed.1002848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。